Etrasimod

Etrasimod
	Skeletal formula of etrasimod
Clinical data
Trade names	Velsipity
Other names	APD334, APD-334
AHFS/Drugs.com	Monograph
MedlinePlus	a623050
License data	US DailyMed: Etrasimod;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
Drug class	Sphingosine-1-phosphate receptor modulator
ATC code	L04AE05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	97.9%
Metabolism	Liver (CYP2C8, 2C9, 3A4)
Elimination half-life	30 hours
Excretion	Feces (82%), kidneys (5%)
Identifiers
	IUPAC name 2-[(3R)-7-{[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy}-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid;
CAS Number	1206123-37-6; as arginine: 1206123-97-8;
PubChem CID	44623998;
DrugBank	DB14766; as arginine: DBSALT003430;
ChemSpider	52084233; as arginine: 57643656;
UNII	6WH8495MMH; as arginine: MXE5EMA09L;
KEGG	D10930; as arginine: D10931;
ChEBI	CHEBI:229230;
ChEMBL	ChEMBL3358920;
Chemical and physical data
Formula	C26H26F3NO3
Molar mass	457.493 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CC[C@@H]5CC(=O)O)C(F)(F)F;
	InChI InChI=1S/C26H26F3NO3/c27-26(28,29)22-11-15(5-8-19(22)16-3-1-2-4-16)14-33-18-7-10-23-21(13-18)20-9-6-17(12-24(31)32)25(20)30-23/h5,7-8,10-11,13,16-17,30H,1-4,6,9,12,14H2,(H,31,32)/t17-/m1/s1; Key:MVGWUTBTXDYMND-QGZVFWFLSA-N;

Etrasimod, sold under the brand name Velsipity, is a medication that is used for the treatment of ulcerative colitis. It is a selective sphingosine-1-phosphate (S1P) receptor modulator that modifies the activity of the immune system. It is taken by mouth.

The most common side effects include lymphopenia (low levels of lymphocytes) and headache.

Etrasimod was discovered by Arena Pharmaceuticals, with subsequent development by Pfizer. Etrasimod was approved for medical use in the United States in October 2023, and in the European Union in February 2024.